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Edited by Beat ImhofAbstract Accumulation of transglutaminase 2 (TG2) is often
associated with mineral deposits in vasculature. Here, we demon-
strate that puriﬁed TG2 stimulated a 3-fold increase in matrix
mineralization and up-regulation of osteoblastic markers in cul-
tured primary vascular smooth muscle cells (VSMCs). Extracel-
lular TG2 interacts with the low density lipoprotein related-
protein 5 receptor and activates b-catenin signaling in VSMCs.
These results suggest that TG2 may promote vascular calciﬁca-
tion by activating the b-catenin signaling pathway.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Vascular calciﬁcation is a common complication of vari-
ous diseases, often resulting in increased mortality. Despite
its clinical importance, the mechanisms controlling vascular
calciﬁcation are not yet understood. Accumulating evidence
for the similarity between the mechanisms of arterial miner-
alization and osteogenesis [1,2] strongly suggests that regula-
tors of bone development may control vascular calciﬁcation.
Moreover, cartilaginous metaplasia and bone-like tissues
such as cartilage, bone marrow and mature lamellar bone
have been identiﬁed in calciﬁed arteries and valves [3,4].
Vascular smooth muscle cells (VSMCs) associated with min-
eralized matrix lose the smooth muscle cell-speciﬁc markers
and exhibit an osteoblast-like phenotype [5–8]. Previously,
we and others have shown that extracellular enzyme trans-
glutaminase 2 (TG2) promotes matrix calciﬁcation and
accelerates diﬀerentiation in cells of osteogenic lineage [9–
12], implicating that it may also aﬀect osteoblastic transfor-
mation of VSMCs.
In vasculature, TG2 is abundantly expressed in various cell
types, including cardiomyocytes, endothelial cells, VSMCs
and macrophages [13,14]. Diverse roles for TG2 have been
documented in cardiovascular pathophysiology (reviewed in
[15]). Under normal physiological conditions, TG2 remains
largely an intracellular protein, which lacks the signal peptide.
However, accumulation of extracellular TG2 has been demon-*Corresponding author. Fax: +1 617 636 3676.
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medial calciﬁcation [16–19], suggesting a role for TG2 in pro-
gression of pathologic vascular calciﬁcation. Moreover,
expression of TG2 by VSMCs appears to be central to their
ability to mineralize matrix [20]. However, the signal transduc-
tion mechanisms of the TG2-regulated calciﬁcation in VSMCs
remain obscure. In this study we investigated the potential of
extracellular TG2 to regulate matrix mineralization and b-
catenin signaling in primary mouse VSMCs, which is essential
for osteoblast diﬀerentiation [21] and its activation correlates
with vascular mineralization [22–24]. Together, our results
identify extracellular TG2 as a novel regulator of the b-catenin
pathway and suggest a molecular mechanism for the TG2-in-
duced cardiovascular calciﬁcation.2. Materials and methods
An expanded Materials and Methods section that describes details
on cell isolation and culture, proliferation assay, RT-PCR, transfection
and analysis of luciferase reporter TOP-FLASH, microarray analysis,
data collection and statistics is available in the online data supplement.
2.1. Mineralization assay
Matrix mineralization was assayed in VSMC cultures seeded at
105 cells/well density in the 24-well plates and induced to mineralize
by chondrocyte-conditioned medium, supplemented with 5 mM b-
glycerophosphate, 25 lg/ml ascorbic acid, and 0.5 mM CaCl2, as de-
scribed [9,25]. Fresh supplements of puriﬁed guinea pig liver TG2
(5 lg/ml) (Sigma) or recombinant Wnt3a (10 ng/ml) (R&D) were
added every other day. Unless otherwise indicated, mineralization
was assessed in the 7 days-old cultures.3. Results
3.1. Extracellular TG2 promotes in vitro vascular calciﬁcation
Calcifying potential of the aortic SMCs depends on the
expression levels of TG2. Importantly, externalization of the
TG2 protein is required for its pro-mineralizing activity
in vitro [20]. Similarly, extracellular TG2 accumulates at sites
of vascular calciﬁcation in medial calciﬁcation and atheroscle-
rotic lesions [16–19]. However, the molecular mechanisms by
which extracellular TG2 aﬀects VSMCs remain largely un-
known. Previously, we demonstrated a rapid (over 7–12 days)
deposition of 50 lg Ca2++/mg protein in VSMC cultures in-
duced to mineralize by the synergistic action of t he chondro-
cyte-derived growth factors and cytokines in the presence of b-
glycerophosphate [25]. Continuous presence of puriﬁed TG2
(5 lg/ml, corresponding to 0.01 U/ml of transamidating activ-ation of European Biochemical Societies.
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(P < 0.03) 1.6-fold increase in VSMC matrix mineralization by
day 8. Further deposition of calciﬁed matrix by VSMCs in the
presence of TG2 resulted in a 3-fold increase (P < 0.05) in min-
eralization by the day 12 of culture (Fig. 1A). Mineral deposi-
tion in VSMC cultures is localized to the matrix with no
accumulation of intracellular mineralized particles. The pat-
tern of matrix calciﬁcation is diﬀuse, unlike the typical nodular
pattern of in vitro calciﬁcation by pericytes or by the stem-like
calcifying vascular cells, suggesting calciﬁcation is driven by
VSMCs.
The TG2-induced increase in VSMC calciﬁcation corre-
lates with a statistically signiﬁcant 1.5 ± 0.1-fold increase in
expression of Cbfa1, a 2.4 ± 0.4-fold increase of the osteo-
calcin transcript, and a dramatic >30-fold increase in bone
sialoprotein transcript determined by the real-time PCR
analysis (data normalized to the b-actin mRNA). These re-
sults indicate that TG2 promotes osteoblastic transformation
characteristic for calcifying VSMCs [5,1,7]. On the contrary,
TG2 does not aﬀect cell proliferation (P = 0.38, Fig. 1B) or
cell death, analyzed by translocation of phosphatidylserine
to the outer leaﬂet of the plasma membrane (which is a uni-
versal apoptotic phenomenon). Further, we have not ob-
served changes in the activity of alkaline phosphatase or
in its expression in response to the TG2 treatment (data
not shown). Thus, the pro-mineralizing eﬀect of TG2 is
not due to a change in cell proliferation or to increased re-
lease of inorganic phosphate from the donor b-glycerophos-
phate. To further corroborate this and to extend our
analysis to native vessel wall, we studied the eﬀect of exog-
enous TG2 on mineralization of cultured arterial rings in the
presence of elevated concentration of inorganic phosphate.
These ex vivo studies (presented in the online data supple-
ment) showed a 2-fold increase in mineralization of arterial
rings caused by addition of TG2 to the medium.
Finally, we observed that regulation of matrix calciﬁcation
by extracellular TG2 is not associated with induction of endog-
enous TG2 (0.95 ± 0.01-fold change in expression in the cells
cultured with or without puriﬁed TG2). This result indicates
that TG2-induced mineralization is not regulated by intracellu-
lar TG2 interactions, but rather – by interactions of extracellu-
lar TG2 with the VSMC surface.Fig. 1. Exogenous TG2 enhances calciﬁcation in mouse VSMCs. (A) Mineral
day 4 (white bars) and reaches the plateau by day 8 (grey bars) without fur
mineralization at day 8 and further increase up to 3-fold by day 12 (*P < 0.053.2. Extracellular TG2 binds LRP5 receptor
Regulation of cell diﬀerentiation by TG2 has been reported
for osteogenic cells [9,10] and for chondrocytes [11]. Previ-
ously, we have shown that the osteoblast-speciﬁc set of TG2-
binding proteins is distinct from the chondrocyte-speciﬁc set,
suggesting regulation of diﬀerent intracellular pathways in
these cell types by TG2. In particular, the ca. 150 kDa protein
band corresponding to integrins, represent the major TG2-
binding protein species in chondrocytes but not in pre-osteo-
blasts [26]. While integrin signaling is central in the TG2-regu-
lated chondrocyte maturation [11], we hypothesize that TG2-
induced osteoblastic diﬀerentiation may be regulated through
an integrin-independent signaling pathway.
To determine such mechanism, we identiﬁed several of the
TG2-binding surface proteins speciﬁc for osteoblasts, using
mass spectrometry. The 180 kDa protein was identiﬁed as a
low-density lipoprotein receptor-related protein (LRP recep-
tor). This was further conﬁrmed by Western blot analysis using
speciﬁc anti-LRP5/6 antibody (H-300 antibody, Santa Cruz)
(unpublished data). Both receptors are known mediators of
the Wnt/b-catenin signaling [27] and both are expressed in
the primary mouse VSMCs employed in our study (Fig. 2A),
in agreement with earlier reports [28]. Here, we demonstrate
using the reciprocal co-immuno-precipitation analysis with
anti-LRP5 and anti-TG2 antibodies that exogenous TG2 binds
the LRP5 receptor on primary mouse VSMCs (Fig. 2B). Sim-
ilarly, TG2 co-immunoprecipitates with the anti-LRP6 anti-
body (data not shown). In the control experiment, an
irrelevant anti-integrin alpha-V antibody did not precipitate
the TG2/LRP5 complex, conﬁrming the speciﬁcity of the anal-
ysis (data not shown). These data suggest that LRP5 is one of
the major TG2-binding surface proteins on mouse VSMCs.
3.3. TG2 activates b-catenin pathway in mouse VSMC
The LRP5/6 receptors are known mediators of the Wnt/b-
catenin signaling [27], suggesting that binding of TG2 to
LRP5 on cell surface of VSMCs may lead to activation of b-
catenin pathway. To test this suggestion, we analyzed the eﬀect
of the TG2 treatment on intracellular localization of b-catenin
in the TG2-treated VSMCs, because nuclear translocation of
b-catenin is the key step of the Wnt/b-catenin signaling path-
way that leads to transcriptional activation by the TCF/LEFization in mouse VSMC grown in the Hyp-CM (control) is detectable at
ther increase by day 12 (black bar). TG2 causes a 1.6-fold increase in
). (B) Cell proliferation in not aﬀected by the presence of puriﬁed TG2.
Fig. 2. (A) Expression of LRP receptors in mouse VSMCs analyzed by RT-PCR (upper panel) expression of (1) LRP6 [product size 215 bp] and (2)
LRP5 [product size 225 bp] and by Western blot with antibodies against LRP5 (C-20) and LRP6 (E-20) (Santa Cruz). (B) Exogenous puriﬁed TG2
binds the LRP5 receptor on mouse VSMCs. Co-immuno-precipitation was performed with either anti-human LRP5 (Santa Cruz) or with anti-TG2
(Upstate Biotech) antibodies. Reciprocal Western blot analyses conﬁrmed the TG2/LRP5 binding.
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nin was detected in the presence of TG2 (Fig. 3A, right panel),
as opposed to the predominantly cytoplasmic localization in
VSMCs in the absence of TG2 (Fig. 3A, left panel).
Activation of the b-catenin pathway by extracellular TG2
was further conﬁrmed using the b-catenin-dependent TCF/
LEF transcriptional luciferase reporter (TOP-FLASH). Treat-
ment of VSMCs with TG2 resulted in a signiﬁcant (P < 0.03)
2.4-fold activation of the TCF-dependent expression of lucifer-
ase (Fig. 3B). The speciﬁcity of the reporter activation was val-
idated using the control reporter construct with the mutated
TCF binding sites (TOP-FLASH), which did not show re-
sponse to TG2 (data not shown). The TG2-induced 3-fold in-
crease in TOP-FLASH expression reﬂects biologically
signiﬁcant activation of b-catenin-dependent transcription, as
has been demonstrated for osteoblasts [30].
To substantiate further activation of the b-catenin pathway
by TG2, we analyzed expression of p21 that is characteristi-Fig. 3. Extracellular TG2 activates b-catenin signaling in mouse VSMCs. (
Nuclei are counterstained with Hoechst dye (lower panel). (B) Puriﬁed TG2 accally down-regulated in response to the b-catenin activation
[31], and observed a signiﬁcant [P < 0.01] 2-fold down-regula-
tion of this gene in VSMCs grown in the presence of TG2 as
compared to the cells grown without TG2 supplement
(Fig. 3C). Thus, our results show that extracellular TG2 acti-
vates the b-catenin signaling pathway in VSMCs.
To evaluate the potency of extracellular TG2 in activation of
the b-catenin pathway, we compared the eﬀects of TG2 to
those induced by a canonical ligand Wnt3a in parallel studies.
Biological activity of puriﬁed TG2 (5 lg/ml) is equivalent to
biological activity of much lower (approximately 250 times)
molar concentration of Wnt3a (10 ng/ml), as determined by
their abilities to cause a similar 3-fold increase in activation
of the TCF/LEF reporter construct TOP-FLASH (P < 0.03)
(Fig. 4A) and in matrix mineralization of VSMCs (Fig. 4B).
The combined treatment of VSMCs with Wnt3a and TG2
did not lead to a cumulative aﬀect, suggesting that both factors
activate mineralization through the same b-catenin pathwayA) TG2 induces nuclear translocation of b-catenin in mouse VSMC.
tivates TOP-FLASH reporter in mouse VSMC (*P < 0.03, **P < 0.03 ).
Fig. 4. TG2 and Wnt3a regulate activation of b-catenin and mineralization in VSMCs. (A) Activation of the TCF/LEF-dependent TOP-FLASH
reporter by recombinant Wnt3a (10 ng/ml) and puriﬁed TG2 (5 lg/ml) in mouse VSMCs (data expressed as luciferase/b-galactosidase). Control
reporter TOP-FLASH did not show any signiﬁcant response to treatments (data not shown). (B) Approximately a 3-fold increase in calciﬁcation of
VSMCs in Hyp-CM is induced by TG2 [P = 0.002], Wnt3a and by the combined treatment with Wnt3a and TG2. *P < 0.05; **P < 0.01.
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this signaling pathway than TG2.
3.4. The Wnt/b-catenin pathway is inherently inactive in VSMCs
despite the presence of the essential components
The b-catenin signaling is known to be inactive in normal
vessels [32]. Our data showed that it is also inactive in VSMC
in vitro, as evidenced by the cytoplasmic localization of b-cate-
nin (Fig. 2B, left panel). However, we also found that extracel-
lular TG2 activates the b-catenin signaling in VSMCs (above),
suggesting that the signaling machinery is present in the cells.
In order to characterize the repertoire of the b-catenin signal-
ing-related proteins in VSMCs, we employed gene microarrays
to analyze expression of the known components of the b-cate-
nin pathway in VSMCs, using the 32K oligonucleotide set
(Qiagen). The results of this analysis are summarized in Table
1. Despite the detected expression of several canonical Wnt li-
gands (Wnt2b, Wnt10b and Wnt 7a) b-catenin remains inac-
tive in VSM cells, suggesting that these regulators may be
expressed at very low levels. In agreement with this suggestion,
the VSMC-conditioned medium failed to induce activation of
TOP-FLASH reporter plasmid in COS-1 cells (Fig. 5A), while
the conventional activator of the Wnt/b-catenin signaling
Wnt3a, used as the positive control, caused a signiﬁcantTable 1
Expression of Wnt signaling-related genes in primary mouse VSMCs
Expressed
Canonical Wnts Wnt2b, Wnt10b, Wnt7a
Non-canonical Wnts Wnt3, Wnt5b, Wnt6, Wnt9
Frz receptors Fz1, Fz2, Fz5, Fz7
LRP co-receptor LRP5, LRP6
Negative regulators of Wnt receptor signaling Axin1, Dkk1, Dkk2, Dkk3
Wnt binding antagonists Sfrp1, Sfrp5
Other genes related to Wnt signaling Bcl9, Csnk2b, Fbxw2, Fshb
Transcription factors Lef1, Tcf1, Tcf4
Some genes related to the canonical Wnt/b-catenin signaling are not annotate
not represented in this table.[P < 0.01] 9-fold increase in the reporter activity. Alternatively,
or in addition to the insuﬃcient levels of ligand expression,
activation of the b-catenin pathway may be blocked by the
antagonists of Wnt signaling expressed by VSMCs, including
the Secreted frizzled related proteins (Sfrp1 and Sfrp5), Wise
and Dikkopf (Dkk 1–4) proteins (Table 1). Next we analyzed
a seemingly discrepancy between the endogenous expression
of TG2 in VSMCs [14], which is able to activate b-catenin
pathway as we have demonstrated, and the inactivity of endog-
enous b-catenin in this cell type. We hypothesize that the cell
surface LRP5 receptor mediates activation of the b-catenin sig-
naling by extracellular TG2. We therefore compared the levels
of endogenous cell surface-associated TG2 to exogenous puri-
ﬁed TG2 used at concentrations suﬃcient to induce matrix
mineralization in VSMCs. For this, VSMCs were released
from the culture plate by brief exposure to trypsin and allowed
to recover in the 10% serum for 4 h. The medium was changes
to serum-free DMEM and cells were incubated with or without
puriﬁed TG2 for 1 h. After ﬁxation with 4% para-formalde-
hyde, cells were processed for immunostaining with anti-TG2
antibody (Fig. 5B). The endogenous levels of TG2 bound to
the cell surface are very low (left lower panel, Fig. 5B), and in-
crease dramatically when cells are exposed to exogenous puri-
ﬁed TG2, which can induce activation of the b-cateninNo expression
Wnt2, Wnt3a, Wnt7b, Wnt8b
b Wnt5a,Wnt10a, Wnt11, Wnt16
Fz3, Fz6, Fz9
, Dkk4, Frzb, Wise Kremen 1, Kremen 2, SOST
Sfrp4
, Fbxw4, Nkd1, Nkd2, Slc9a3r1, Rhou
Tcf2
d on the 32 K oligonucletide array (Qiagen-Operon) and therefore are
Fig. 5. (A) Endogenous activators of the Wnt/b-catenin signaling
secreted by the mouse VSMCs are insuﬃcient to induce expression of
the TOP-FLASH reporter in COS-1 cells (medium conditioned by
mouse VSMC, VSMC-CM, grey bar), as compared to the control cells
(plain medium, white bar), or cells treated with the puriﬁed Wnt3a
(10 ng/ml) (black bar), **P < 0.01. (B) Immunostaining of the cell
bound TG2 (lower panels). Endogenous levels of TG2 are very low in
untreated VSMCs (control), while exogenous puriﬁed TG2 binds
eﬃciently (+TG2). Top panels – light microscopy view of the same
ﬁeld.
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that there is a threshold in the levels of extracellular activators
of the b-catenin pathway in VSMCs, which is insuﬃcient to
activate b-catenin signaling under normal conditions.4. Discussion
Various TGases have been implicated in many roles in both
normal embryonic and postnatal tissues and in diverse pathol-
ogies, in particular in vascular diseases (reviewed in [13,15]). A
role for extracellular TG2 in regulation of vascular calciﬁca-
tion has been suggested by the reported accumulation of this
protein at the sites of vascular calciﬁcation [16–19]. Recent
study by Johnson et al. conﬁrmed a central role for TG2 in cal-
ciﬁcation of arterial smooth muscle cells [20]. Our study de-
scribes a novel molecular mechanism by which extracellular
TG2 enhances calciﬁcation and osteoblastic-transformation
in VSMCs. We demonstrate that puriﬁed TG2 added to cell
cultures of primary mouse VSMCs binds LRP5 receptor and
activates the b-catenin signaling pathway, as indicated by the
hallmark events characteristic for such activation including nu-
clear translocation of b-catenin, induction of the TCF/LEF
transcription factors, and a decrease in p21 expression. Our re-
sults of the gene expression survey and the supporting experi-
ments indicate that the intrinsic inactivity of the Wnt/b-catenin
signaling in VSMCs [33,32] is caused by low levels of the
endogenous activating ligands. Indeed, over-expression of the
LRP6 receptor alone is insuﬃcient to activate the TCF/LEFtranscription factors in VSMCs, but requires co-expression
of Wnt1 for this activation [28]. In our experiments, this insuf-
ﬁciency can be oﬀset by addition of Wnt3a or puriﬁed TG2,
leading to activation of the b-catenin and an increase in min-
eralization. In vasculature, activation of the b-catenin signal-
ing pathway is associated with diverse cardiovascular
disorders and speciﬁcally with calciﬁcation of the aortic valves
[23,24] and with the medial calciﬁcation in the type II diabetes
[22,34]. However, the regulators of this pathway in mineraliz-
ing vascular walls remain largely unknown. Our studies pro-
vide direct evidence for the pro-mineralization role of the
Wnt/b-catenin signaling in vascular cells, and conﬁrm that
TG2 may act as one of its regulators. In addition to activating
b-catenin in calcifying VSMCs, we demonstrate that exoge-
nous TG2 also up-regulates the key osteogenic transcription
factor Cbfa1 as well as osteocalcin and bone sialoprotein,
which are the downstream targets of Cbfa1 [36]. Considering
that transciption of Cbfa1 is directly regulated by the activity
of canonical Wnt/b-catenin signaling [35], our results strongly
suggest that TG2-induced activation of b-catenin pathway
leads to osteoblastic transformation of VSMCs and their calci-
ﬁcation. Precise extracellular interactions underlying the pro-
mineralizing activity of TGases [9,11,10,12] remain obscure.
In particular, the input of the catalytic transamidating activity
versus the non-enzymatic activities of TG2, including its ability
to bind matrix proteins and cell surface receptors such as ﬁbro-
nectin, integrins [37] and LRP5 (as shown here), remain to be
determined. The TG2-induced increase in calciﬁcation is not
associated with a signiﬁcant change in pattern of cross-linked
proteins in the VSMC cultures (our unpublished data), sug-
gesting a minor role for the catalytic activity in the regulation
of matrix mineralization. This proposition is supported by
only partial attenuation of calciﬁcation in non-mineralizing
TG2/ smooth muscle cells by catalytically active exogenous
TG2 [20]. Alternatively, a TG2-induced cross-linking of just a
few proteins, such as osteopontin [38,19], may be suﬃcient to
enhance calciﬁcation and promote osteoblast-like transforma-
tion in VSMCs. Identiﬁcation of these proteins would be rele-
vant for further understanding of the molecular regulation of
vascular calciﬁcation.
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